2024
The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges
Puzo C, Li P, Tormey C, Siddon A. The effect of plerixafor on autologous stem cell mobilization, cell viability, and apheresis challenges. Lab Medicine 2024, 56: 187-194. PMID: 39303673, DOI: 10.1093/labmed/lmae080.Peer-Reviewed Original ResearchAutologous stem cell transplantationHematopoietic stem cellsMultiple myelomaG-CSFMobilization failureDiffuse large B-cell lymphomaAutologous stem cell mobilizationLarge B-cell lymphomaGranulocyte colony-stimulating factorAutologous stem cell transplant patientsEfficacy of plerixaforStem cell mobilizationB-cell lymphomaStem cell transplantationEffects of plerixaforRetrospective chart reviewColony-stimulating factorYale-New Haven HospitalCell viabilityMultiple risk factorsHodgkin lymphomaNon-HodgkinMobilization regimenCell transplantationPlerixaforOmission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study.
Peng C, Saffo S, Oberstein P, Shusterman M, Thomas C, Becker D, Berlin J, Leichman L, Boursi B, Nagar A, Yu S. Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study. Journal Of The National Comprehensive Cancer Network 2024, 22: 521-527. PMID: 39236754, DOI: 10.6004/jnccn.2024.7029.Peer-Reviewed Original ResearchMultidrug regimensFOLFIRINOX regimensAdvanced colorectalGastrointestinal cancerAssociated with decreased survivalGranulocyte colony-stimulating factorCompare survival outcomesGastrointestinal cancer treatmentBaseline clinical factorsKaplan-Meier analysisFirst-line FOLFOXMulticenter cohort studyColony-stimulating factorInverse probability of treatmentAdvanced gastrointestinal cancerTreatment selection biasProbability of treatmentHealth care savingsCox proportional hazardsOverall survivalEffective regimenIPTW analysisSurvival outcomesPancreatic cancerAssociated with reductionsSmall-molecule CBP/p300 histone acetyltransferase inhibition mobilizes leukocytes from the bone marrow via the endocrine stress response
Jaschke N, Breining D, Hofmann M, Pählig S, Baschant U, Oertel R, Traikov S, Grinenko T, Saettini F, Biondi A, Stylianou M, Bringmann H, Zhang C, Yoshida T, Weidner H, Poller W, Swirski F, Göbel A, Hofbauer L, Rauner M, Scheiermann C, Wang A, Rachner T. Small-molecule CBP/p300 histone acetyltransferase inhibition mobilizes leukocytes from the bone marrow via the endocrine stress response. Immunity 2024, 57: 364-378.e9. PMID: 38301651, PMCID: PMC10923082, DOI: 10.1016/j.immuni.2024.01.005.Peer-Reviewed Original ResearchConceptsCorticotropin-releasing hormone receptor 1Hypothalamus-pituitary-adrenal glandAdrenocorticotropic hormoneBone marrowGranulocyte colony-stimulating factorAugmented host defenseMobilization of leukocytesColony-stimulating factorHistone acetyltransferase inhibitionHormone receptor 1Leukemic transformationG-CSFNeutrophil mobilizationReceptor 1Leukocyte mobilizationLeukocyte distributionHistone acetyltransferaseLeukocyte compartmentNeuroendocrine loopHost defenseEndocrine stress responseLeukocytesMarrowBloodReversible inhibition
2022
Human neutrophil development and functionality are enabled in a humanized mouse model
Zheng Y, Sefik E, Astle J, Karatepe K, Öz HH, Solis AG, Jackson R, Luo HR, Bruscia EM, Halene S, Shan L, Flavell RA. Human neutrophil development and functionality are enabled in a humanized mouse model. Proceedings Of The National Academy Of Sciences Of The United States Of America 2022, 119: e2121077119. PMID: 36269862, PMCID: PMC9618085, DOI: 10.1073/pnas.2121077119.Peer-Reviewed Original ResearchConceptsHumanized mouse modelMouse modelHuman immune systemHuman neutrophilsImmune systemFunctional human immune systemGranulocyte colony-stimulating factorUnique mouse modelColony-stimulating factorHuman G-CSFMISTRG miceG-CSF receptor geneBacterial burdenInfectious challengeG-CSFNeutrophilsMiceNeutrophil developmentReceptor geneDiseaseTROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-naïve patients (pts) with metastatic urothelial cancer (mUC).
Tagawa S, Grivas P, Petrylak D, Sternberg C, Swami U, Bhatia A, Pichardo C, Goswami T, Loriot Y. TROPHY-U-01 cohort 4: Sacituzumab govitecan (SG) in combination with cisplatin (Cis) in platinum (PLT)-naïve patients (pts) with metastatic urothelial cancer (mUC). Journal Of Clinical Oncology 2022, 40: tps581-tps581. DOI: 10.1200/jco.2022.40.6_suppl.tps581.Peer-Reviewed Original ResearchMetastatic urothelial cancerBlinded independent central reviewObjective response rateSacituzumab govitecanOverall survivalDay 1Antibody-drug conjugatesCohort 4Eastern Cooperative Oncology Group performance status 0Prophylactic granulocyte colony-stimulating factorActive interstitial lung diseaseAntigen 2 antibodiesClinical benefit ratePerformance status 0Phase 2 doseStudy drug initiationMedian overall survivalProgression-free survivalPhase 2 trialDose-limiting toxicityInterstitial lung diseaseDuration of responseEfficacy/safetyGranulocyte colony-stimulating factorIndependent central reviewThe ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question
O’Brien S, Badawy SM, Rotz SJ, Shah MD, Makarski J, Bercovitz RS, Hogan MS, Luchtman-Jones L, Panepinto JA, Priola GM, Witmer CM, Wolfson JA, Yee M, Hicks LK. The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question. Blood Advances 2022, 6: 679-685. PMID: 35072726, PMCID: PMC8791561, DOI: 10.1182/bloodadvances.2020003635.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHealth care providersAsymptomatic childrenHematologic testsFamily historyCare providersRed blood cell transfusionChoosing Wisely projectBlood cell transfusionPediatric Hematology/OncologyGranulocyte colony-stimulating factorChoosing Wisely campaignHistory of recurrentChoosing Wisely recommendationsIron deficiency anemiaPositive family historyHematology/oncologyQuality improvement initiativesAmerican SocietyColony-stimulating factorInternal Medicine FoundationAutoimmune neutropeniaActive bleedingCell transfusionPlatelet transfusionsTask Force
2021
Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease
Shah NC, Bhoopatiraju S, Abraham A, Anderson E, Andreansky M, Bhatia M, Chaudhury S, Cuvelier GDE, Godder K, Grimley M, Hale G, Kamani N, Jacobsohn D, Ngwube A, Gilman AL, Skiles J, Yu LC, Shenoy S. Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated following Allogeneic Transplantation in Patients with Sickle Cell Disease. Transplantation And Cellular Therapy 2021, 28: 174.e1-174.e5. PMID: 34958973, DOI: 10.1016/j.jtct.2021.12.016.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationSickle cell diseaseNeutrophil recoveryG-CSFCell diseaseReduced-intensity conditioning hematopoietic stem cell transplantationReversible posterior leukoencephalopathy syndromeCalcineurin inhibitor therapyHemoglobin S levelPosterior leukoencephalopathy syndromeLife-threatening complicationsG-CSF useGranulocyte-colony stimulating factorStem cell infusionStem cell transplantationGranulocyte colony-stimulating factorG-CSF initiationAvailable stem cell sourceStem cell sourceColony-stimulating factorLeukoencephalopathy syndromeSickle vasculopathyHSCT recipientsNeutrophil engraftmentPlatelet engraftmentThe ASH‐ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question
O'Brien SH, Badawy SM, Rotz SJ, Shah MD, Makarski J, Bercovitz RS, Hogan M, Luchtman‐Jones L, Panepinto JA, Priola GM, Witmer CM, Wolfson JA, Yee M, Hicks LK. The ASH‐ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question. Pediatric Blood & Cancer 2021, 68: e28967. PMID: 34047047, DOI: 10.1002/pbc.28967.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHealth care providersAsymptomatic childrenHematologic testsFamily historyCare providersRed blood cell transfusionChoosing Wisely projectProphylaxis of childrenBlood cell transfusionPediatric Hematology/OncologyGranulocyte colony-stimulating factorChoosing Wisely campaignHistory of recurrentChoosing Wisely recommendationsIron deficiency anemiaPositive family historyHematology/oncologyQuality improvement initiativesAmerican SocietyColony-stimulating factorInternal Medicine FoundationAutoimmune neutropeniaActive bleedingCell transfusionPlatelet transfusionsCirculating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma
Chehrazi-Raffle A, Meza L, Alcantara M, Dizman N, Bergerot P, Salgia N, Hsu J, Ruel N, Salgia S, Malhotra J, Karczewska E, Kortylewski M, Pal S. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma. Journal For ImmunoTherapy Of Cancer 2021, 9: e002009. PMID: 33688021, PMCID: PMC7944971, DOI: 10.1136/jitc-2020-002009.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factor tyrosine kinase inhibitorMetastatic renal cell carcinomaRenal cell carcinomaImmune checkpoint inhibitorsColony-stimulating factorClinical benefitPlasma cytokinesSystemic therapyCell carcinomaInterleukin-6Prospective correlative studyLines of therapyLow pretreatment levelsGranulocyte colony-stimulating factorGranulocyte-macrophage colony-stimulating factorRCC histologic subtypesMacrophage colony-stimulating factorICI armsICI therapyStable diseaseCheckpoint inhibitorsClinical responsePartial responseComplete responseImmunologic profileA neutrophil activation signature predicts critical illness and mortality in COVID-19
Meizlish ML, Pine AB, Bishai JD, Goshua G, Nadelmann ER, Simonov M, Chang CH, Zhang H, Shallow M, Bahel P, Owusu K, Yamamoto Y, Arora T, Atri DS, Patel A, Gbyli R, Kwan J, Won CH, Dela Cruz C, Price C, Koff J, King BA, Rinder HM, Wilson FP, Hwa J, Halene S, Damsky W, van Dijk D, Lee AI, Chun HJ. A neutrophil activation signature predicts critical illness and mortality in COVID-19. Blood Advances 2021, 5: 1164-1177. PMID: 33635335, PMCID: PMC7908851, DOI: 10.1182/bloodadvances.2020003568.Peer-Reviewed Original ResearchConceptsCritical illnessHealth system databaseNeutrophil activationCOVID-19Neutrophil activation signatureSevere COVID-19Intensive care unitGranulocyte colony-stimulating factorHigh mortality rateColony-stimulating factorSystem databaseHepatocyte growth factorClinical decompensationNeutrophil countImmune hyperactivationCare unitEarly elevationLipocalin-2Interleukin-8Longitudinal cohortClinical dataMortality ratePatientsIllnessActivation signature
2020
Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease
Shah N, Bhoopatiraju S, Abraham A, Anderson E, Andreansky M, Bhatia M, Chaudhury S, Cuvelier G, Godder K, Grimley M, Hale G, Kamani N, Jacobsohn D, Ngwube A, Skiles J, Yu L, Shenoy S. Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease. Blood 2020, 136: 33. DOI: 10.1182/blood-2020-142696.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseAbsolute neutrophil countVaso-occlusive episodesG-CSF administrationNeutrophil recoveryG-CSFSCD patientsCell diseaseDay 100Unrelated donor hematopoietic cell transplantationDonor hematopoietic cell transplantationVaso-occlusive pain crisesHemoglobin S levelPrimary graft rejectionShort-course methotrexateAcute chest syndromeLife-threatening complicationsG-CSF useGranulocyte-colony stimulating factorGranulocyte colony-stimulating factorTranscranial Doppler velocitiesDifferent donor sourcesColony-stimulating factorSafety/toxicityConsiderations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic.
Griffiths EA, Alwan LM, Bachiashvili K, Brown A, Cool R, Curtin P, Geyer MB, Gojo I, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Lyman GH, Mukherjee S, Perez LE, Rosovsky RP, Roy V, Rugo HS, Vasu S, Wadleigh M, Westervelt P, Becker PS. Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 Pandemic. Journal Of The National Comprehensive Cancer Network 2020, 19: 1-4. PMID: 32871558, PMCID: PMC9730290, DOI: 10.6004/jnccn.2020.7610.Peer-Reviewed Original ResearchErythrocyte-stimulating agentsHematopoietic growth factorsGrowth factorSARS-CoV-2 infectionPandemic SARS-CoV-2 infectionGranulocyte colony-stimulating factorColony-stimulating factorTreatment of cancerThrombopoietin mimeticsHigh riskSuch growth factorsStimulating agentsPatientsCancerCOVID-19 eraCOVID-19 pandemicInfectionHigh-risk environmentsNeutropeniaThrombocytopeniaMorbidityChemotherapyFactorsAnemiaGroupTransplant in Aplastic Anemia Using Combined Granulocyte Colony-Stimulating Factor Primed Blood and Bone Marrow Stem Cells: A Retrospective Analysis
Ali N, Butt A, Altaf B, Adil SN, Shaikh MU. Transplant in Aplastic Anemia Using Combined Granulocyte Colony-Stimulating Factor Primed Blood and Bone Marrow Stem Cells: A Retrospective Analysis. Transplantation Proceedings 2020, 53: 386-390. PMID: 32773285, DOI: 10.1016/j.transproceed.2020.06.035.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnemia, AplasticChildChild, PreschoolFemaleGraft vs Host DiseaseGranulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedPeripheral Blood Stem Cell TransplantationPostoperative ComplicationsRetrospective StudiesTransplantation ConditioningYoung AdultConceptsBone marrow stem cellsAplastic anemiaMarrow stem cellsOverall survivalAntithymocyte globulinAllogeneic hematopoietic stem cell transplantHematopoietic stem cell transplantStem cellsStudy periodFrequency of GVHDHost disease (GVHD) prophylaxisStandard infection prophylaxisOnly curative optionBone marrow graftsStem cell transplantGranulocyte colony-stimulating factorColony-stimulating factorAga Khan UniversityAcute GVHDChronic GVHDConditioning regimenCurative optionTransplant outcomesAllogeneic transplantsConditioning regimensNeutropenic Enterocolitis: Clinical Features and Outcomes.
Abu-Sbeih H, Ali F, Chen E, Mallepally N, Luo W, Lu Y, Foo W, Qiao W, Okhuysen P, Adachi J, Hachem R, Altan M, Jenq R, Wang Y. Neutropenic Enterocolitis: Clinical Features and Outcomes. Diseases Of The Colon & Rectum 2020, 63: 381-388. PMID: 31842164, DOI: 10.1097/dcr.0000000000001548.Peer-Reviewed Original ResearchConceptsMD Anderson Cancer CenterNeutropenic enterocolitisGranulocyte colony-stimulating factorAnderson Cancer CenterCancer CenterColony-stimulating factorMucosal injuryClinical featuresSurvival rateTexas MD Anderson Cancer CenterConcomitant systemic infectionImmunosuppressive therapy useDuration of neutropeniaRetrospective cohort studyAbsolute neutrophil countCox regression analysisComprehensive cancer centerLower survival rateAbdominal symptomsEnterocolitis diagnosisEnterocolitis symptomsNeutropenia onsetPneumatosis intestinalisCohort studyColonic perforation
2016
Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever
Tsao C, Galsky M, Oh W. Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever. European Urology 2016, 70: 707-708. PMID: 27417033, DOI: 10.1016/j.eururo.2016.06.041.Peer-Reviewed Original ResearchConceptsNeutropenic feverProstate cancerMetastatic castration-sensitive prostate cancerMetastatic hormone-sensitive prostate cancerProphylactic granulocyte colony-stimulating factorCastration-sensitive prostate cancerRisk of neutropenic feverHormone-sensitive prostate cancerGranulocyte colony-stimulating factorCastration-resistant diseaseColony-stimulating factorAssociated with higher ratesDocetaxel treatmentRisk factorsFeverCancerHigher RatesRiskNeutropeniaDocetaxel
2015
Protective role of G-CSF in dextran sulfate sodium-induced acute colitis through generating gut-homing macrophages
Meshkibaf S, Martins A, Henry G, Kim S. Protective role of G-CSF in dextran sulfate sodium-induced acute colitis through generating gut-homing macrophages. Cytokine 2015, 78: 69-78. PMID: 26687628, DOI: 10.1016/j.cyto.2015.11.025.Peer-Reviewed Original ResearchMeSH KeywordsAdoptive TransferAnimalsCells, CulturedColitisDextran SulfateGranulocyte Colony-Stimulating FactorHomeostasisInterleukin-13Interleukin-1betaIntestinesLipopolysaccharidesMacrophage Colony-Stimulating FactorMacrophagesMiceNitric Oxide Synthase Type IIReceptors, Granulocyte Colony-Stimulating FactorTumor Necrosis Factor-alphaConceptsInducible nitric oxide synthaseBone marrow-derived macrophagesG-CSFMarrow-derived macrophagesColony-stimulating factorAcute colitisDextran sulfate sodium-induced acute colitisSeverity of colitisDextran sulfate sodiumReceptor-deficient miceGranulocyte colony-stimulating factorDeath ligand 2Function of neutrophilsNitric oxide synthaseTumor necrosis factorMacrophage colony-stimulating factorRegulatory macrophage markersAdoptive transferSulfate sodiumIL-1βImmune homeostasisOxide synthaseMacrophage markersNecrosis factorImmune regulationPhase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma
Galsky M, Hahn N, Wong B, Lee K, Argiriadi P, Albany C, Gimpel-Tetra K, Lowe N, Shahin M, Patel V, Tsao C, Oh W. Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. Cancer Chemotherapy And Pharmacology 2015, 76: 1259-1265. PMID: 26464352, DOI: 10.1007/s00280-015-2884-7.Peer-Reviewed Original ResearchConceptsSecond-line therapyAdvanced urothelial carcinomaMetastatic urothelial cancerUrothelial carcinomaFebrile neutropeniaUrothelial cancerAdverse eventsHigh risk of febrile neutropeniaManagement of metastatic urothelial cancerPatient died of neutropenic sepsisProphylactic granulocyte colony-stimulating factorEpisodes of febrile neutropeniaRisk of febrile neutropeniaGranulocyte colony-stimulating factorDose of amrubicinMetastatic urothelial carcinomaSingle-agent activityFirst-line chemotherapyPhase 2 trialPatient selection biomarkerColony-stimulating factorAdministered to patientsSynthetic anthracyclineTopoisomerase II inhibitorsStable disease
2012
Localized Mucosal Response to Intranasal Live Attenuated Influenza Vaccine in Adults
Barría MI, Garrido JL, Stein C, Scher E, Ge Y, Engel SM, Kraus TA, Banach D, Moran TM. Localized Mucosal Response to Intranasal Live Attenuated Influenza Vaccine in Adults. The Journal Of Infectious Diseases 2012, 207: 115-124. PMID: 23087433, PMCID: PMC3571238, DOI: 10.1093/infdis/jis641.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntranasalAdolescentAdultAnimalsAntibodies, ViralCohort StudiesCytokinesDogsFemaleHemagglutinin Glycoproteins, Influenza VirusHumansImmunity, MucosalImmunoglobulin AInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza B virusInfluenza VaccinesInfluenza, HumanMadin Darby Canine Kidney CellsMaleMiddle AgedNasal Lavage FluidVaccinationVaccines, AttenuatedVaccines, InactivatedYoung AdultConceptsNasal washesInfluenza vaccineMajor public health burdenSerum G-CSF levelsLive attenuated influenza vaccineAttenuated influenza vaccineImmunoglobulin A (IgA) antibodiesLow serum levelsGranulocyte colony-stimulating factorImmunoglobulin G levelsInfluenza virus infectionG-CSF levelsPublic health burdenColony-stimulating factorInterferon response genesMucosal responsesSerum levelsMucosal IgAIP-10Local inflammationAntibody responseTrivalent vaccineA antibodiesHealth burdenLocalized inflammationSuccessful collection and engraftment of autologous peripheral blood progenitor cells in poorly mobilized patients receiving high‐dose granulocyte colony‐stimulating factor
Cooper DL, Proytcheva M, Medoff E, Seropian SE, Snyder EL, Krause DS, Wu Y. Successful collection and engraftment of autologous peripheral blood progenitor cells in poorly mobilized patients receiving high‐dose granulocyte colony‐stimulating factor. Journal Of Clinical Apheresis 2012, 27: 235-241. PMID: 22566214, DOI: 10.1002/jca.21232.Peer-Reviewed Original ResearchConceptsHigh-dose G-CSFAutologous HPC transplantationHematopoietic progenitor cellsG-CSFHPC transplantationProgenitor cellsAutologous peripheral blood progenitor cell collectionHigh-dose granulocyte colony-stimulating factorAutologous peripheral blood progenitor cellsRetrospective medical record reviewPeripheral blood progenitor cell collectionPeripheral blood progenitor cellsMedical record reviewGranulocyte-colony stimulating factorGranulocyte colony-stimulating factorBlood progenitor cellsEfficacy of mobilizationProgenitor cell harvestsProgenitor cell collectionColony-stimulating factorPlatelet engraftmentRecord reviewSafety profileGood mobilizersPeripheral blood
2011
Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution
Cooper DL, Pratt K, Baker J, Medoff E, Conkling-Walsh A, Foss F, Snyder E, Yen W, Seropian SE. Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution. Clinical Lymphoma Myeloma & Leukemia 2011, 11: 267-272. PMID: 21658654, DOI: 10.1016/j.clml.2011.03.014.Peer-Reviewed Original ResearchConceptsStem cell mobilizationEnough stem cellsMultiple myelomaCell mobilizationG-CSFPrevious mobilizationGranulocyte colony-stimulating factorNon-Hodgkin lymphomaStem cellsG-CSF mobilizationColony-stimulating factorPrevious chemotherapyPrevious therapyMobilization failurePoor mobilizationEvening injectionsCD34 countHigh riskPatientsPlerixaforCell countCost-effective useMyelomaLenalidomideChemotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply